Ionis Pharmaceuticals IONS Accrued Clinical Expenses
Accrued Clinical Expenses at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:AccruedClinicalExpenses.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's accrued clinical expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's accrued clinical expenses?
- Ionis Pharmaceuticals (IONS) reported accrued clinical expenses of $53.33M in Q1 2026.
- How has Ionis Pharmaceuticals's accrued clinical expenses changed year-over-year?
- Ionis Pharmaceuticals's accrued clinical expenses decreased by 21.1% year-over-year, from $67.61M to $53.33M.
- What does accrued clinical expenses mean?
- Unpaid costs for clinical trials that have already been conducted.
- How do you interpret accrued clinical expenses?
- An increase typically signals active, ongoing clinical trial enrollment and research activity, while a decrease may indicate the completion of major study phases.
- How does accrued clinical expenses compare across companies?
- Standard liability for clinical-stage biotech companies, reflecting the intensity of the R&D pipeline.